Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy Virtual 2020 | PTC596: inhibiting BMI1 in myeloma

Heinz Ludwig • 12 May 2020
COMy Virtual 2020
Multiple Myeloma PTC596

Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, talks on the promise of PTC596 – an oral BMI1 inhibitor – for the treatment of multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Heinz Ludwig

2:50
Immunotherapy highlights at IMS 2023: bispecific antibodies, CAR-T cells & unanswered questions
Heinz Ludwig • 27 Sep 2023
2:02
Issues with CAR-T slot allocation in myeloma & the promise of locally manufactured products
Heinz Ludwig • 27 Sep 2023
3:49
Advances in technologies used to assess immune function in myeloma
Heinz Ludwig • 27 Sep 2023
2:59
Managing COVID-19 risks and exposures in patients with myeloma
Heinz Ludwig • 12 May 2023

Related Videos

History and upcoming projects of the MMRF
Hearn Jay Cho et al. • 3 May 2024
7:50
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
Alexander Lyon • 25 Apr 2024
Novel targets & agents in myeloma
Faith Davies et al. • 3 May 2024
Session highlights: sequencing CAR-T cells & bispecifics and managing toxicities
Faith Davies et al. • 3 May 2024
The content of VJHemOnc is intended for healthcare professionals